

CBD of Denver Inc.

Amendment to Quarterly Report March 31, 2025 Quarterly Disclosure and Financial Statements for 03/31/2025 originally published through the OTC Disclosure & News Service on [05/14/2025](#)

Explanatory Note:

Added the financial statements that were inadvertently left off original filing

***This coversheet was automatically generated by OTC Markets Group based on the information provided by the Company. OTC Markets Group has not reviewed the contents of this amendment and disclaims all responsibility for the information contained herein.*

CBD of Denver Inc.
Industriestrasse 31, 8305 Dietlikon, Switzerland

+41 (0) 44 2440034
<https://www.luxora-holding.com/en>
info@cbdofdenver.com

Quarterly Report

For the period ending March 31, 2025 (the “Reporting Period”)

Outstanding Shares

The number of shares outstanding of our Common Stock was:

8,925,546,030 as of March 31, 2025 (Current Reporting Period Date or More Recent Date)

7,899,998,300 as of December 31, 2024 (Most Recent Completed Fiscal Year End)

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Change in Control

Indicate by check mark whether a Change in Control⁴ of the company has occurred during this reporting period:

Yes: ☐ No: ☒

⁴ “Change in Control” shall mean any events resulting in:

(i) Any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

11/16/2018	CBD of Denver Inc.
09/15/2010	Verde Media Group, Inc.
04/13/2007	Hidalgo Mining International
1993	Communication Corp of America

Current State and Date of Incorporation or Registration: Delaware, 01/05/2010

Standing in this jurisdiction: (e.g. active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years:

N/A

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

None

List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

NA

Address of the issuer's principal executive office:

Industriestrasse 31, 8305 Dietlikon, Switzerland

Address of the issuer's principal place of business:

☒ *Check if principal executive office and principal place of business are the same address:*

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: ☒ Yes: ☐ If Yes, provide additional details below:

2) Security Information

Transfer Agent

Name: Olde Monmouth Stock Transfer Co., Inc.
Phone: (732) 872-2727
Email: matt@oldemonmouth.com
Address: 200 Memorial Pkwy, Atlantic Heights, NJ 07716

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol:	<u>CBDD</u>
Exact title and class of securities outstanding:	<u>Common Stock</u>
CUSIP:	<u>12482B107</u>
Par or stated value:	<u>\$0.00001</u>
Total shares authorized:	<u>11,500,000,000</u> <u>as of date: 3/31/2025</u>
Total shares outstanding:	<u>8,925,546,030</u> <u>as of date: 3/31/2025</u>
Total number of shareholders of record:	<u>250</u> <u>as of date: 3/31/2025</u>

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

Other classes of authorized or outstanding equity securities that do not have a trading symbol:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of the security:	Series A Preferred	
CUSIP (if applicable):	N/A	
Par or stated value:	<u>\$0.00001</u>	
Total shares authorized:	<u>88,500,000</u>	<u>as of date: 3/31/2025</u>
Total shares outstanding (if applicable):	<u>34,000</u>	<u>as of date: 3/31/2025</u>
Total number of shareholders of record (if applicable):	<u>2</u>	<u>as of date: 3/31/2025</u>

Exact title and class of the security:	Series B Preferred	
CUSIP (if applicable):	N/A	
Par or stated value:	<u>\$0.0001</u>	
Total shares authorized:	<u>1,500,000</u>	<u>as of date: 3/31/2025</u>
Total shares outstanding (if applicable):	<u>12,000</u>	<u>as of date: 3/31/2025</u>
Total number of shareholders of record (if applicable):	<u>3</u>	<u>as of date: 3/31/2025</u>

Exact title and class of the security:	Series C Preferred	
CUSIP (if applicable):	N/A	
Par or stated value:	<u>\$0.0001</u>	
Total shares authorized:	<u>10,000,000</u>	<u>as of date: 3/31/2025</u>

Total shares outstanding (if applicable):	9,566,259	<u>as of date: 3/31/2025</u>
Total number of shareholders of record (if applicable):	<u>1</u>	<u>as of date: 3/31/2025</u>

Exact title and class of the security:	Series D Super Voting Preferred Stock	
CUSIP (if applicable):	N/A	
Par or stated value:	\$0.0001	
Total shares authorized:	1	<u>as of date: 3/31/2025</u>
Total shares outstanding (if applicable):	1	<u>as of date: 3/31/2025</u>
Total number of shareholders of record (if applicable):	<u>1</u>	<u>as of date: 3/31/2025</u>

Exact title and class of the security:	Series E Preferred Stock	
CUSIP (if applicable):	N/A	
Par or stated value:	\$0.0001	
Total shares authorized:	10,000	<u>as of date: 3/31/2025</u>
Total shares outstanding (if applicable):	10,000	<u>as of date: 3/31/2025</u>
Total number of shareholders of record:	<u>2</u>	<u>as of date: 3/31/2025</u>

Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

Each share of common stock has the right to one vote per share on all matters voted on by the shareholders. The holders of common stock are entitled to receive dividends as declared by the Board of Directors out of funds legally available therefor. The holders of common stock have no preemptive or subscription rights and there are no redemption or sinking fund provisions applicable to the common stock.

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

Series A Preferred

Each share of Series A Preferred Stock is convertible into 1,500 shares of Common Stock and has voting rights equal to 1,500 shares of Common Stock.

Subsequent to 12/31/2022 and as of the date hereof, the Series A Preferred Stock has been exchanged for 10,000,000 shares of Series C Preferred Stock. Each share of the Series C Preferred Stock is convertible into 1,500 shares of Common Stock, subject to maximum conversion limitations, but has no voting rights.

Series B Preferred

Series B Preferred Stock accrue a dividend at the rate of 5% of the Series B Original Issue Price (\$10 per share) per annum. Such accrued and unpaid dividend shall be convertible into shares of Common Stock of the Company.

Each share of Series B Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into that number of fully paid and nonassessable shares of Common Stock (whether whole or fractional) that have a Fair Market Value, in the aggregate, equal to the Series B Original Issue Price, as adjusted as provided herein. "Fair Market Value" shall mean as of any date of determination, 80% of the average closing price of a share of Common Stock on the principal exchange or market on which such shares are then trading for the 5 trading days immediately preceding such date. Therefore, to determine the number of shares issuable the Series B Original Issue Price, as adjusted, is divided by the Fair Market Value, the quotient being the number of shares of Common Stock issued upon conversion. For example, if the Series B Original Issue Price is \$10 and the Fair Market Value is \$.005, then $10.00/.005 = 2,000$ shares of Common stock would be issued.

Series C Preferred

The holders of the Series C Preferred Stock shall be entitled to any dividend that is payable to the holders of the Corporation's Common Stock. The Series C Preferred Stock will, with respect to dividend rights and rights upon liquidation, winding-up or dissolution, rank: (a) senior to the Corporation's Common Stock, \$0.001 par value per share ("Common Stock"); (b) senior with respect to any other series of Preferred Stock, as set forth in the Certificate of Designations with respect to such Preferred Stock; and (c) junior to all existing and future indebtedness of the Corporation.

Except as provided by law or by the other provisions of the Articles of Incorporation or this designation, holders of Series C Preferred Stock shall have no voting rights.

Each share of Series C Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into 1,500 (One Thousand Five Hundred) fully paid and nonassessable shares of Common Stock. The conversion right is subject to maximum conversion limitations of 4.9% of the total issued and outstanding shares of Company Common Stock, which may be waived on 61 days' notice, but in any case, may not exceed 9.999% of the total issued and outstanding shares of Company Common Stock.

Series D Preferred

The holder of the Series D Preferred is entitled to cast that number of votes on all matters presented for stockholder vote to the stockholders of the Corporation that when taking into account the votes entitled to be cast by the Series D Preferred stockholder is equal to seventy-five percent (75%) of the total shares authorized to vote on such matter(s) and such holder shall vote along with holders of the Corporation's Common Stock on such matters.

The Series D has no pre-emptive or conversion rights.

Series E Preferred

The holders of the Series E Preferred Stock shall be entitled to any dividend that is payable to the holders of the Corporation's Common Stock.

In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, each share of Series E Preferred Stock shall automatically be converted into shares of Common Stock at the then applicable conversion rate.

On any matter presented to the shareholders of the Corporation for their action or consideration at any meeting of shareholders of the Corporation (or by written consent of shareholders in lieu of meeting), each holder of outstanding shares of Series E Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series E Preferred Stock held by such holder are convertible.

Each share of Series E Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into that number of fully paid and nonassessable shares of Common Stock (whether whole or fractional) equal to 0.05% of the total number of shares of Common Stock outstanding at the Conversion Time.

3. **Describe any other material rights of common or preferred stockholders.**

NA

4. **Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.**

NA

3) Issuance History

*The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.***

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: ☐ Yes: ☒ (If yes, you must complete the table below)

Shares Outstanding as of Second Most Recent Fiscal Year End: <u>Opening Balance</u> Date <u>12/31/2021</u> Common: <u>5,309,588,107</u> Preferred: <u>10,000,000</u>			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to. *You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
<u>March 16, 2022</u>	<u>New Issuance</u>	<u>200,000,000</u>	<u>Common Stock</u>	<u>.00126</u>	<u>Yes</u>	<u>Capitoline Venture Fund II LLC</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>Section 4(a)(1)</u>

						Robert Roever			
<u>July 14, 2022</u>	<u>New Issuance</u>	4,666,666	<u>Common Stock</u>	\$0.004	<u>Yes</u>	<u>Hanspeter Vocheze</u>	<u>Cash</u>	<u>Restricted</u>	<u>Section 4(a)(2)</u>
<u>July 21, 2022</u>	<u>New Issuance</u>	5,000	<u>Series B Preferred</u>	\$10,00	<u>No</u>	<u>Kenneth Feinstein</u>	<u>Cash</u>	<u>Restricted</u>	<u>Section 4(a)(2)</u>
<u>August 31, 2022</u>	<u>New Issuance</u>	4,800,000	<u>Common Stock</u>	\$0.00250	<u>Yes</u>	<u>Henry Wilsher</u>	<u>Cash</u>	<u>Restricted</u>	<u>Section 4(a)(2)</u>
<u>August 31, 2022</u>	<u>New Issuance</u>	12,500,000	<u>Common Stock</u>	\$0.00200	<u>Yes</u>	<u>Shane Attersley</u>	<u>Cash</u>	<u>Restricted</u>	<u>Section 4(a)(2)</u>
<u>August 31, 2022</u>	<u>New Issuance</u>	17,500,000	<u>Common Stock</u>	\$0.00200	<u>Yes</u>	<u>Gavin Solomon</u>	<u>Cash</u>	<u>Restricted</u>	<u>Section 4(a)(2)</u>
<u>August 31, 2022</u>	<u>New Issuance</u>	25,000,000	<u>Common Stock</u>	\$0.00200	<u>Yes</u>	<u>Offelbar PTY Ltd.</u> <u>Quentin Flannery</u>	<u>Cash</u>	<u>Restricted</u>	<u>Section 4(a)(2)</u>
<u>August 31, 2022</u>	<u>New Issuance</u>	7,400,000	<u>Common Stock</u>	\$0.00250	<u>Yes</u>	<u>David Gibson</u>	<u>Cash</u>	<u>Restricted</u>	<u>Section 4(a)(2)</u>
<u>September 22, 2022</u>	<u>New Issuance</u>	2,000	<u>Series B Preferred</u>	\$10.00	<u>No</u>	<u>BMO Nesbitt Burns ITF – Rachel Gurney</u>	<u>Cash</u>	<u>Restricted</u>	<u>Section 4(a)(2)</u>
<u>December 7, 2022</u>	<u>New Issuance</u>	5,000	<u>Series B Preferred</u>	\$10.00	<u>No</u>	<u>Thomas J. Porcaro</u>	<u>Cash</u>	<u>Restricted</u>	<u>Section 4(a)(2)</u>
<u>January 25, 2023</u>	<u>New Issuance</u>	68,933,333	<u>Common Stock</u>	\$.0015	<u>No</u>	<u>Legendary Life GmbH</u> <u>Jeff Yribarren</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
<u>March 24, 2023</u>	<u>New Issuance</u>	349,611,000	<u>Common Stock</u>	.0003	<u>No</u>	<u>Goldberg AG</u> <u>Pascal Siegenthaler</u>	<u>Conversion of Series C Preferred Stock</u>	<u>Unrestricted</u>	<u>Section 4(a)(1)</u>
<u>March 24, 2023</u>	<u>Cancellation</u>	(233,074)	<u>Series C Preferred</u>	N/A	<u>N/A</u>	<u>Goldberg AG</u> <u>Pascal Siegenthaler</u>	<u>Conversion to Common</u>	<u>N/A</u>	<u>Section 3(a)(9)</u>
<u>August 1, 2023</u>	<u>New Issuance</u>	34,000,000	<u>Common Stock</u>	.0004	<u>No</u>	<u>Axel Reinke</u>	<u>Director Fee</u>	<u>Restricted</u>	<u>Section 4(a)(2)</u>
<u>August 1, 2023</u>	<u>New Issuance</u>	34,000,000	<u>Common Stock</u>	.0004	<u>No</u>	<u>Robert Roever</u>	<u>Director Fee</u>	<u>Restricted</u>	<u>Section 4(a)(2)</u>
<u>August 1, 2023</u>	<u>New Issuance</u>	34,000,000	<u>Common Stock</u>	.0004	<u>No</u>	<u>Nicholas Sprung</u>	<u>Director Fee</u>	<u>Restricted</u>	<u>Section 4(a)(2)</u>
<u>August 1, 2023</u>	<u>New Issuance</u>	250,000,500	<u>Common Stock</u>	N/A	<u>No</u>	<u>Goldberg AG</u> <u>Pascal Siegenthaler</u>	<u>Conversion of Series C Preferred Stock</u>	<u>Unrestricted</u>	<u>Section 4(a)(1)</u>
<u>August 1, 2023</u>	<u>Cancellation</u>	(166,667)	<u>Series C Preferred</u>	N/A	<u>N/A</u>	<u>Goldberg AG</u> <u>Pascal Siegenthaler</u>	<u>Conversion to Common</u>	<u>N/A</u>	<u>Section 3(a)(9)</u>
<u>August 1, 2023</u>	<u>New Issuance</u>	10,180,000	<u>Common Stock</u>	.0024	<u>No</u>	<u>Adam Cairns</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
<u>August 1, 2023</u>	<u>New Issuance</u>	20,000,000	<u>Common Stock</u>	.0024	<u>No</u>	<u>Rasa Marinkovic</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
<u>November 20, 2023</u>	<u>New Issuance</u>	199,999,500	<u>Common Stock</u>	Na	<u>Na</u>	<u>Goldberg AG</u> <u>Pascal Siegenthaler</u>	<u>Conversion to Common</u>	<u>N/A</u>	<u>Section 3(a)(9)</u>
<u>November 20, 2023</u>	<u>New Issuance</u>	32,000,000	<u>Common Stock</u>	.0004	<u>No</u>	<u>Nicholas Sprung</u>	<u>Director Fee</u>	<u>Restricted</u>	<u>Section 4(a)(2)</u>

<u>November 20, 2023</u>	<u>New Issuance</u>	32,000,000	<u>Common Stock</u>	.0004	<u>No</u>	<u>Robert Roever</u>	<u>Director Fee</u>	<u>Restricted</u>	<u>Section 4(a)(2)</u>
<u>November 20, 2023</u>	<u>New Issuance</u>	32,000,000	<u>Common Stock</u>	.0004	<u>No</u>	<u>Axel Reinke</u>	<u>Director Fee</u>	<u>Restricted</u>	<u>Section 4(a)(2)</u>
<u>April 18, 2024</u>	<u>New Issuance</u>	86,472,603	<u>Common Stock</u>		<u>No</u>	<u>Thomas J. Porcaro</u>	<u>Conversion of Series B Preferred</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>April 18, 2024</u>	<u>Cancellation</u>	5,000	<u>Series B Preferred</u>			<u>Thomas J. Porcaro</u>			
<u>April 18, 2024</u>	<u>New Issuance</u>	124,803,000	<u>Common Stock</u>	.0003	<u>No</u>	<u>Goldberg AG Pascal Siegenthaler</u>	<u>Conversion of Series C Preferred</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>April 18, 2024</u>	<u>Cancellation</u>	(83,202)	<u>Series C Preferred</u>			<u>Pascal Siegenthaler</u>			
<u>April 22, 2024</u>	<u>New Issuance</u>	110,545,091	<u>Common Stock</u>		<u>No</u>	<u>Kenneth Feinstein</u>	<u>Conversion of Series B Preferred</u>	<u>unrestricted</u>	<u>4(a)(1)</u>
<u>April 22, 2024</u>	<u>Cancellation</u>	(5,000)	<u>Series B Preferred</u>			<u>Kenneth Feinstein</u>			
<u>August 1, 2024</u>	<u>New Issuance</u>	249,999,000	<u>Common</u>	.0003	<u>no</u>	<u>GB II Partners, Inc./ Pascal Siegenthaler</u>	<u>Conversion of Series C Preferred</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>September 26, 2024</u>	<u>New Issuance</u>	300,000,000	<u>Common</u>	.0003	<u>no</u>	<u>GB II Partners, Inc./ Pascal Siegenthaler</u>	<u>Conversion of Series C Preferred</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>November 19, 2024</u>	<u>New Issuance</u>	349,999,500	<u>Common</u>	.0003	<u>n/a</u>	<u>GB II Partners, Inc./ Pascal Siegenthaler</u>	<u>Conversion of Series C Preferred</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>February 12, 2025</u>	<u>New Issuance</u>	310,143,730	<u>Common</u>	0.0003	<u>n/a</u>	<u>Pascal Siegenthaler</u>	<u>Conversion to Common</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>March 5, 2025</u>	<u>New Issuance</u>	715,404,000	<u>Common</u>	0.0003	<u>n/a</u>	<u>GB II Partners, Inc./ Pascal Siegenthaler</u>	<u>Conversion of Series C Preferred</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
Shares Outstanding on Date of This Report:									
<u>Ending Balance:</u>									
Date <u>03/31/2025</u> Common: 8,925,546,030									
Preferred: 9,519,057									

Example: A company with a fiscal year end of December 31st 2024, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2023 through December 31, 2024 pursuant to the tabular format above.

Any additional material details, including footnotes to the table are below:

B. Convertible Debt

The following is a complete list of the Company's Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

☐ Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$) (include accrued interest)	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion ⁵	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g., Loan, Services, etc.)
March 8, 2023	\$730,234	\$788,338	04/30/26	the average of the lowest intraday trading prices during the 20 (twenty) days prior to the day that the Holder requests conversion.	0	7,883,380,000	Capitoline Ventures II LLC Robert Roevers	Loan memorializing advances from 2020 through 2022
Total Outstanding Balance:		\$788,338	Total Shares:		0	7,883,380,000		

Any additional material details, including footnotes to the table are below:

4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. Ensure that these descriptions are updated on the Company's Profile on www.OTCMarkets.com.

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Through its Luxora Inc. subsidiary, the Company operates in the hemp and CBD market, focusing exclusively on wholesale distribution. Luxora provides consulting services related to cultivation, legal, and compliance aspects within the sector.

B. List any subsidiaries, parent company, or affiliated companies.

Luxora Inc.
Luxora Holding AG
HOLISTICH GmbH

C. Describe the issuers' principal products or services.

Luxora Inc. specializes in unlocking the potential of the legalized cannabis market, offering a range of CBD health and wellness products, along with consulting services tailored to support the evolving legal cannabis industry.

5) Issuer's Facilities

The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

⁵ The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

The Company maintains office space in Zurich, Switzerland at a cost of CHF 4,250 (approximately \$4,700) per month

6) All Officers, Directors, and Control Persons of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities.

If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.

Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, 5% Control person)	City and State (Include Country if outside U.S.)	Number of Shares Owned (List common, preferred, warrants and options separately)	Class of Shares Owned	Percentage of Class of Shares Owned (undiluted)
<u>Jan Schwager</u>	<u>CEO/Director</u>	<u>Zurich, Switzerland</u>	none	-	-
<u>Robert Roever</u>	<u>Director</u>	<u>New York, NY</u>	<u>34,000,000</u> <u>1</u> <u>5,000</u>	<u>Common</u> <u>Series D</u> <u>Preferred</u> <u>Series E</u> <u>Preferred</u> <u>(1)</u>	<u>Less than</u> <u>1%</u> <u>100%</u> <u>50%</u>
<u>GBII Partners Inc. (2)</u>	<u>5% Holder</u>	<u>Zurich, Switzerland</u>	9,349,724	<u>Series C</u> <u>Preferred</u>	<u>Pascal</u> <u>Siegenthaler</u>

1. The Series E Preferred Shares are subject to vesting upon the achievement of certain milestones.
2. GBII Partners Inc. is not a control person or affiliate of the Company. GBII acquired the Series C Preferred shares in exchange for Series A Preferred Shares that it received pursuant to execution on a pledge agreement with Swiss Industry Ventures AG. The Series C Preferred Shares are subject to a conversion limitation of 9.9% of common.

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, log in to www.OTCIQ.com to update your company profile.

7) Legal/Disciplinary History

- A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

No

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

No

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

No

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

No

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

No

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

No

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

NA

8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, update your company profile.

Securities Counsel

Name: Jonathan Leinwand, Esq.
Firm: Jonathan D. Leinwand, P.A.
Address 1: 18305 Biscayne Blvd., Suite 200
Address 2: Aventura, FL 33160
Phone: 954-903-7856
Email: jonathan@jdlpa.com

Accountant or Auditor

Name: Ralph Klemen
Firm: Vabera GmbH
Address 1: Zuercherstrasse 20
Address 2: 8952 Schlieren, Switzerland
Phone: +41 43 499 09 09
Email: r.klemen@vabera.ch

Investor Relations

Name: N/A
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

All other means of Investor Communication:

X (Twitter): @LUXORA Inc
Discord: N/A
LinkedIn: N/A
Facebook: N/A
Instagram: @luxorainc @luxora_ch

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: N/A
Firm: N/A
Nature of Services: N/A
Address 1: N/A
Address 2: N/A

Phone: N/A
Email: N/A

9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: Jan Schwager
Title: CEO
Relationship to Issuer: CEO

B. The following financial statements were prepared in accordance with:

- ☐ IFRS
☒ U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: Ralph Klemenz
Title: Accountant
Relationship to Issuer: outside Accountant

Describe the qualifications of the person or persons who prepared the financial statements:⁶ Mr. Klemenz is an accountant with over 5 years of experience preparing financial statements for companies.

Provide the following qualifying financial statements:

- Audit letter, if audited;
- Balance Sheet;
- Statement of Income;
- Statement of Cash Flows;
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- Financial Notes

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be "machine readable". Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

10) Issuer Certification

Principal Executive Officer:

⁶ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Jan Schwager certify that:

1. I have reviewed this Disclosure Statement for CBD of Denver, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

05/9/2025 [Date]

/S/ Jan Schwager [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, Jan Schwager certify that:

1. I have reviewed this Disclosure Statement for CBD of Denver, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

05/9/2025 [Date]

/S/ Jan Schwager [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

CBD OF DENVER, INC.

**FINANCIAL REPORT
(Unaudited)**

**At March 31, 2025 and December 31, 2024, and
For the Three Months ended March 31, 2025 and 2024**

CBD OF DENVER, INC.

INDEX

	PAGE
DISCLAIMER REPORT	2
CONSOLIDATED BALANCE SHEETS	3
CONSOLIDATED STATEMENTS OF OPERATIONS	4
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)	5
CONSOLIDATED STATEMENTS OF CASH FLOWS	6
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS	7-16

DISCLAIMER REPORT

To Management and Board of Directors
CBD of Denver, Inc.

The accompanying consolidated financial statements of CBD of Denver, Inc. and the relating financial statements of the subsidiaries as of March 31, 2025 and December 31, 2024, and for the three month ended March 31, 2025 and 2024, were not subject to an audit, review or compilation engagement by us and, we do not express an opinion, a conclusion, nor provide any assurance on the data presented.

Ralph Klemenz, Phone: +41 43 499 09 09
Vabera GmbH, Tax and Accounting Services
Zürcherstrasse 20
8952 Schlieren

May 7, 2025

CBD OF DENVER, INC.

CONSOLIDATED BALANCE SHEETS
(unaudited)

	March 31, <u>2025</u>	December 31, <u>2024</u>
ASSETS		
Current Assets:		
Cash and cash equivalents	\$ 8,516	\$ 35,119
Accounts receivable	-	5,642
Inventory	-	-
Total Current Assets	<u>8,516</u>	<u>40,761</u>
Fixed assets	-	-
Total Assets	<u>\$ 8,516</u>	<u>\$ 40,761</u>
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current Liabilities:		
Accounts payable	\$ 139,165	\$ 121,189
Accrued expenses	223,689	185,759
Others payable	2,190	2,190
Dividend payable	4,917	4,917
Capitoline Ventures LLC Note (Note 3)	979,650	979,650
Goldberg AG Note	-	-
Pascal Siegenthalert Note (Note 3)	-	83,571
Total Current Liabilities	<u>1,349,611</u>	<u>1,377,276</u>
Total Liabilities	<u>1,349,611</u>	<u>1,377,276</u>
Commitments and Contingencies (Note 4)	-	-
Shareholders' Equity:		
Series A Preferred stock, par value \$0.00001, 88,500,000 shares authorized; 34,000 shares issued and outstanding as of March 31, 2025		
34,000 shares issued and outstanding as of December 31, 2024	1	1
Series B Preferred stock, par value \$0.0001, 1,500,000 shares authorized; 12,000 shares issued and outstanding as of March 31, 2025		
12,000 shares issued and outstanding as of December 31, 2024	1	1
Series C Preferred stock, par value \$0.00001, 10,000,000 shares authorized; 9,566,259 shares issued and outstanding as of March 31, 2025		
9,566,259 shares issued and outstanding as of December 31, 2024	96	96
Series D Super Voting Preferred Stock, par value \$0.0001, 1 share authorized 1 share issued and outstanding as of March 31, 2025 resp. December 31, 2024	-	-
Series E Preferred Stock, par value \$0.0001, 10,000 shares authorized 10,000 shares issued and outstanding as per March 31, 2025 resp. December 31, 2024	1	1
Common stock, par value \$0.00001, 11,500,000,000 shares authorized; 8,925,546,030 shares issued and outstanding as of March 31, 2025		
7,899,998,300 shares issued and outstanding as of December 31, 2024	89,255	79,000
Additional paid-in capital	3,760,870	3,760,870
Statutory Reserved	1,246	1,246
Retained Earnings (Accumulated deficit)	(5,124,334)	(5,109,499)
Accumulated other comprehensive income	(68,231)	(68,231)
Total Shareholders' Equity (Deficit)	<u>(1,341,095)</u>	<u>(1,336,515)</u>
Total Liabilities and Shareholders' Equity (Deficit)	<u>\$ 8,516</u>	<u>\$ 40,761</u>

The accompanying notes are an integral part of these financial statements.

CBD OF DENVER, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)

	For the Three Months Ended March 31,	
	<u>2025</u>	<u>2024</u>
Revenue		
Sales	\$ 557,116	\$ 1,123,322
Cost of Goods Sold	<u>(520,791)</u>	<u>(975,945)</u>
Gross Profit	<u>36,325</u>	<u>147,377</u>
Operating Expenses		
Marketing fees	4,585	9,107
Salaries	4,580	91,686
Professional fees	12,574	2,901
Consultant fees	9,521	1,079
Office expenses	2,547	15,107
Rental expenses	6,854	10,310
Depreciation	-	-
Other general and administration expenses	-	-
Total Operating Expenses	<u>40,661</u>	<u>130,190</u>
Net Income from Operations	(4,336)	17,187
Other Income (Expenses)		
Interest expenses	(120,499)	(113,844)
Gain on disposal of subsidiary		
Loss on disposal of assets		
Loss on debt settlement	-	-
Total Other Income (Expenses)	<u>(120,499)</u>	<u>(113,844)</u>
Net Income before Provision for Income Tax	(124,835)	(96,657)
Prior year adjustment of Accounts Payables and Accrued Expenses	110,000	-
Income Tax Provision	-	-
Net Income	<u>\$ (14,835)</u>	<u>\$ (96,657)</u>
Other comprehensive income (loss)	-	55,777
Total comprehensive income (loss)	<u>\$ (14,835)</u>	<u>\$ (40,880)</u>
Basic loss per Share	<u>\$ (0.00)</u>	<u>\$ (0.00)</u>
Diluted loss per Share	<u>\$ (0.00)</u>	<u>\$ (0.00)</u>
Weighted average shares outstanding-Basic	8,589,088,502	5,701,876,340
Effect of dilutive Series A Preferred Stock*	51,000,000	51,000,000
Effect of dilutive Series B Preferred Stock**	125,000,000	125,000,000
Effect of dilutive Series C Preferred Stock***	10,138,464,583	10,138,464,583
Weighted average shares outstanding-diluted	<u>18,903,553,085</u>	<u>16,016,340,923</u>

* All of the Company's Series A Preferred Stock is convertible into shares of common stock at a rate of 1,500 shares of common stock for every preferred share. 15,000,000,000 shares of common stock issuable to preferred shareholders.

** Each share of Series B Preferred Stock shall be convertible, at the option of the holder thereof, into common stocks, as more fully disclosed in Note 3, Stock Capital.

*** Each share of Series C Preferred Stock shall be convertible, at the option of the holder thereof, into common stocks, as more fully disclosed in Note 3, Stock Capital.

The accompanying notes are an integral part of these financial statements.

CBD OF DENVER, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)
(unaudited)

	Series A Preferred Stock \$0.00001 Par Value		Series B Preferred Stock \$0.00001 Par Value		Series C Preferred Stock \$0.00001 Par Value		Common Stock \$0.00001 Par Value		Additional Paid-in Capital	Statutory Reserved	Retained Earnings (Accumulated Deficit)	Accumulated Other Comprehensive Income	Total Shareholders' Equity (Deficit)
	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount					
Balances at January 1, 2023	10,000,000	\$ 100	12,000	\$ 1	-	\$ -	\$ 5,481,844,273	\$ 55,815	\$ 3,529,400	\$ 1,246	\$ (5,431,480)	\$ (124,008)	\$ (1,968,926)
Preferred A stocks were converted to Preferred C stocks	(9,966,000)	(99)	-	-	9,966,000	100	-	-	(1.00)	-	-	-	-
Preferred C stocks were converted to common stocks	-	-	-	-	(233,074)	(2)	349,611,000	3,496	(3,494.00)	-	-	-	-
Issuance of common stock	-	-	-	-	-	-	68,933,333	689	102,711.00	-	-	-	103,401
Balances at March 31, 2023	<u>34,000</u>	<u>\$ 1</u>	<u>12,000</u>	<u>\$ 1</u>	<u>9,732,926</u>	<u>\$ 98</u>	<u>\$ 5,900,388,606</u>	<u>\$ 60,000</u>	<u>\$ 3,628,616</u>	<u>\$ 1,246</u>	<u>\$ (5,495,824)</u>	<u>\$ (68,233)</u>	<u>\$ (1,874,094)</u>
Balances at June 30, 2023	<u>34,000</u>	<u>\$ 1</u>	<u>12,000</u>	<u>\$ 1</u>	<u>9,732,926</u>	<u>\$ 98</u>	<u>\$ 5,900,388,606</u>	<u>\$ 60,000</u>	<u>\$ 3,628,616</u>	<u>\$ 1,246</u>	<u>\$ (5,534,877)</u>	<u>\$ (68,231)</u>	<u>\$ (1,913,145)</u>
Preferred C stocks were converted to common stocks	-	-	-	-	(166,667)	(2)	349,611,000	3,496	(3,494.00)	-	-	-	-
Issuance of common stock	-	-	-	-	-	-	132,180,000	1,322	51,550.00	-	-	-	52,872
To accrue dividend payable for Series B Preferred Stock	-	-	-	-	-	-	-	-	-	-	(1,500)	-	(1,500)
Net income (loss)	-	-	-	-	-	-	-	-	-	-	(132,547)	-	(132,547)
Other comprehensive income (loss)	-	-	-	-	-	-	-	-	-	-	-	-	-
Balances at September 30, 2023	<u>34,000</u>	<u>\$ 1</u>	<u>12,000</u>	<u>\$ 1</u>	<u>9,566,259</u>	<u>\$ 96</u>	<u>\$ 6,382,179,606</u>	<u>\$ 64,818</u>	<u>\$ 3,676,672</u>	<u>\$ 1,246</u>	<u>\$ (5,668,924)</u>	<u>\$ (68,231)</u>	<u>\$ (1,994,320)</u>
Preferred C stocks were converted to common stocks	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of common stock	-	-	-	-	-	-	295,999,500	1,964	996.00	-	-	-	2,960
To accrue dividend payable for Series B Preferred Stock	-	-	-	-	-	-	-	-	-	-	-	-	-
Net income (loss)	-	-	-	-	-	-	-	-	-	-	639,355	-	639,355
Other comprehensive income (loss)	-	-	-	-	-	-	-	-	-	-	-	-	-
Balances at December 31, 2023	<u>34,000</u>	<u>\$ 1</u>	<u>12,000</u>	<u>\$ 1</u>	<u>9,566,259</u>	<u>\$ 96</u>	<u>\$ 6,678,179,106</u>	<u>\$ 66,782</u>	<u>\$ 3,677,668</u>	<u>\$ 1,246</u>	<u>\$ (5,029,569)</u>	<u>\$ (68,231)</u>	<u>\$ (1,352,005)</u>
Preferred C stocks were converted to common stocks	-	-	-	-	-	-	1,221,819,194	12,218	83,202	-	-	-	95,420
Issuance of common stock	-	-	-	-	-	-	-	-	-	-	-	-	-
To accrue dividend payable for Series B Preferred Stock	-	-	-	-	-	-	-	-	-	-	-	-	-
Net income (loss)	-	-	-	-	-	-	-	-	-	-	(79,930)	-	(79,930)
Other comprehensive income (loss)	-	-	-	-	-	-	-	-	-	-	-	-	-
Balances at December 31, 2024	<u>34,000</u>	<u>\$ 1</u>	<u>12,000</u>	<u>\$ 1</u>	<u>9,566,259</u>	<u>\$ 96</u>	<u>\$ 7,899,998,300</u>	<u>\$ 79,000</u>	<u>\$ 3,760,870</u>	<u>\$ 1,246</u>	<u>\$ (5,109,499)</u>	<u>\$ (68,231)</u>	<u>\$ (1,336,515)</u>
Issuance of common stock	-	-	-	-	-	-	1,025,547,730	10,255	-	-	-	-	10,255
Net income (loss)	-	-	-	-	-	-	-	-	-	-	(14,835)	-	(14,835)
Balances at March 31, 2024	<u>34,000</u>	<u>\$ 1</u>	<u>12,000</u>	<u>\$ 1</u>	<u>9,566,259</u>	<u>\$ 96</u>	<u>\$ 8,925,546,030</u>	<u>\$ 89,255</u>	<u>\$ 3,760,870</u>	<u>\$ 1,246</u>	<u>\$ (5,124,334)</u>	<u>\$ (68,231)</u>	<u>\$ (1,341,095)</u>

The accompanying notes are an integral part of these financial statements.

CBD OF DENVER, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

	For the Three Months Ended March 31,	
	<u>2025</u>	<u>2024</u>
<u>Cash Flows from Operating Activities</u>		
Net Income	\$ (14,835)	\$ (31,852)
Adjustments to reconcile net income (loss) to net cash provided (used) by operating activities:		
Depreciations		
Stock compensation expense	-	-
Changes in operating assets and liabilities		
Decrease/(Increase) in accounts receivable	5,642	34,500
Decrease/(Increase) in others receivable	-	-
Decrease/(Increase) in prepaid expenses	-	-
Decrease/(Increase) in receivable from public authorities	-	-
Decrease/(Increase) in inventories	-	-
Increase/(Decrease) in notes	(83,571)	-
Increase/(Decrease) in accounts payable	17,976	(3,863)
Increase/(Decrease) in others payable	-	(30,772)
Increase/(Decrease) in accrued interest	-	31,520
Increase/(Decrease) in accrued expenses	37,930	-
Net cash used by operating activities	<u>(36,858)</u>	<u>(467)</u>
<u>Cash Flows from Investing Activities</u>		
Purchase of equipment	<u>-</u>	<u>-</u>
Net cash provided (used) by investing activities	<u>-</u>	<u>-</u>
<u>Cash Flows from Financing Activities</u>		
Proceeds from issuance of Series B Preferred Stock	-	-
Proceeds from issuance of common stock	10,255	-
Repayment of loans from a related party	-	-
Proceeds from Capitoline Ventures Note	-	-
proceeds from Goldberg AG Note	-	-
proceeds from Pascal Siegenthaler Note	-	-
Net cash provided (used) by financing activities	<u>(26,603)</u>	<u>(467)</u>
Increase (decrease) in cash	(26,603)	(467)
Effects of exchange rates change on cash	-	-
Cash at beginning of period	35,119	23,875
Cash at end of period	<u>\$ 8,516</u>	<u>\$ 23,408</u>
Supplemental Disclosures of Cash Flow Information:		
Cash paid during the year for:		
Interest	\$ <u>-</u>	\$ <u>-</u>
Income tax	\$ <u>-</u>	\$ <u>-</u>
Non-cash financing activities		
Settlement of notes with comment stock	\$ <u> </u>	\$ <u> </u>

The accompanying notes are an integral part of these financial statements.

CBD OF DENVER, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Note 1 - DESCRIPTION OF BUSINESS AND SUMMARY OF ACCOUNTING PRINCIPLES

CBD of Denver Inc. (“CBDD,” “we,” “our,” or the “Company”), was formed as a corporation in the state of Nevada on March 2, 2007. On January 5, 2010 we filed a certificate of conversion from a non-Delaware corporation pursuant to Section 265 of the Delaware General Corporation Law. The Company has developed its own brand of CBD products and related social networking.

In January 2023, the Company acquired 100% equity ownership interest in Libra, which is engaged in the business of magic lappen and anti-slip product. As per June 30, 2024, both parties have agreed to unwind the transaction and are now awaiting signatures.

Going Concern

As of March 31, 2025 and December 31, 2024, the Company had an accumulated deficit of \$5,124,334 and \$5,109,499 respectively. These factors raise a substantial doubt about the Company’s ability to continue as a going concern. The Company plans to increase its income by strengthening its sales force, providing attractive sales incentive program, and increasing marketing and promotion activities. Management also intends to raise additional funds by way of a private or public offering, or by obtaining loans from banks or others. While the Company believes in the viability of its strategy to generate sufficient revenue and in its ability to raise additional funds on reasonable terms and conditions, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds by way of a public or private offering. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Income Taxes

The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible. When appropriate, a valuation allowance is established to eliminate the Company’s deferred tax assets if it is more likely than not that none of the deferred tax assets will be realized.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Income Taxes (continued)

The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon settlement with the tax authorities. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest related to unrecognized tax benefits in interest expense and penalties in income tax expense. The Company has determined that it had no significant uncertain tax positions requiring recognition or disclosure.

The Company accounts for income taxes in interim periods in accordance with FASB ASC 740-270, "Interim Reporting." The Company has determined an estimated annual effective tax rate. The rate will be revised, if necessary, as of the end of each successive interim period during the Company's fiscal year to its best current estimate. The estimated annual effective tax rate is applied to the year-to-date ordinary income (or loss) at the end of the interim period.

Revenue Recognition

Pursuant to ASC Topic 606, Revenue from Contracts with Customers, or ASC 606, the Company recognizes revenue upon transfer of control of goods, in an amount that reflects the consideration that is expected to be received in exchange for those goods. The Company does not allow for the return of products so does not establish an allowance for returns.

Topic 606 established that the Company recognize revenue using the following five-step model:

- Identification of the contract, or contracts, with a customer;
- Identification of the performance obligations in the contract;
- Determination of the transaction price;
- Allocation of the transaction price to the performance obligations in the contract; and
- Recognition of revenue when or as, the Company satisfies a performance obligation.

Revenue is recognized at the point in the time once the Company satisfies its performance obligation which occurs when title and possession of products have transitioned to the customer, typically upon delivery of the products.

CBD OF DENVER, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

Note 1- DESCRIPTION OF BUSINESS AND SUMMARY OF ACCOUNTING PRINCIPLES
(continued)

Stock-Based Compensation

The Company accounts for share-based compensation awards in accordance with ASC 718, "Compensation – Stock Compensation". The cost of services received from employees and non-employees in exchange for awards of equity instruments is recognized in the consolidated statement of operations based on the estimated fair value of those awards on the grant date and amortized on a straight-line basis over the requisite service period or vesting period. The Company records forfeitures as they occur.

Earnings Per Share

Earnings per share is computed by dividing net income by the weighted-average number of shares outstanding. To the extent that outstanding securities are anti-dilutive, they are excluded from the calculation of diluted earnings per share.

Impairment of long-lived assets

The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. No impairment of long-lived assets was recognized for the three months ended March 31, 2025 and 2024.

Foreign Currency Translation

The functional currency of our international subsidiaries is the local currency. We translate the financial statements of these subsidiaries to U.S. dollars using year-end rates of exchange for assets and liabilities, and average rates of exchange for revenue, costs, and expenses. Translation gains and losses are recorded in accumulated other comprehensive income as a component of stockholders' equity.

The exchange rates used to translate amounts in CHF into U.S. Dollars for the purposes of preparing the consolidated financial statements are as follows:

March 31, 2025

1 CHF = 1.1257 USD

The average exchange rate in the three months ended March 31, 2025

1 CHF = 1.0987 USD

Segments

Our chief operating decision-maker is our Chief Executive Officer who makes resource allocation decisions and assesses performance based on financial information presented on a consolidated basis. There are no segment managers who are held accountable by the chief operating decision-maker, or anyone else, for operations, operating results, and planning for levels or components below the consolidated unit level. Accordingly, we have determined that we have a single reportable segment and operating segment structure.

Leases

The Company follows ASC 842 and determines if an arrangement is a lease or contains a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, and operating lease liabilities (current and non-current) in the Company’s consolidated balance sheets. Finance leases are included in property and equipment, and finance lease liabilities (current and non-current) in the Company’s consolidated balance sheets.

The Company has elected not to recognize lease assets and liabilities for leases with an initial term of 12 months or less.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to credit risk consist primarily of accounts and other receivables. The Company does not require collateral or other security to support these receivables. The Company conducts periodic reviews of the financial condition and payment practices of its customers to minimize collection risk on accounts receivable.

For the three months ended March 31, 2025 and 2024, no customer accounted for more than 10% of the Company’s total sales.

For the three months ended March 31, 2025 and 2024, no vender accounted for more than 10% of the Company’s total purchase.

CBD OF DENVER, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

Note 1- DESCRIPTION OF BUSINESS AND SUMMARY OF ACCOUNTING PRINCIPLES (continued)

Fair Value of Measurements

The Company adopted FASB ASC 820 “Fair Value Measurements,” which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Additionally, the inputs used to measure fair value are prioritized based on a three-level hierarchy. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

- | | |
|-----------------|--|
| Level 1: | Unadjusted quoted prices in active markets for identical assets or liabilities. |
| Level 2: | Input other than quoted market prices that are observable, either directly or indirectly, and reasonably available. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the Company. |
| Level 3: | Unobservable inputs. Unobservable inputs reflect the assumptions that the Company develops based on available information about what market participants would use in valuing the asset or liability. |

An asset or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Availability of observable inputs can vary and is affected by a variety of factors. The Company uses judgment in determining fair value of assets and liabilities, and Level 3 assets and liabilities involve greater judgment than Level 1 and Level 2 assets or liabilities.

As of the balance sheet date, the estimated fair values of the financial instruments approximated their fair values due to the short-term nature of these instruments.

CBD OF DENVER, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

Note 1- DESCRIPTION OF BUSINESS AND SUMMARY OF ACCOUNTING PRINCIPLES
(continued)

Use of Estimates

In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On a continual basis, management reviews its estimates, utilizing currently available information, changes in facts and circumstances, historical experience, and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates.

Research and Development Costs

Research and development costs relating to the development of new products and processes, including significant improvements and refinements to existing products, are expensed when incurred in accordance with the FASB ASC 730, "Research and Development." Research and development costs were immaterial for the years ended December 31, 2024 and 2023.

Related Parties

The Company adopted FASB ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

CBD OF DENVER, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

Note 1- DESCRIPTION OF BUSINESS AND SUMMARY OF ACCOUNTING PRINCIPLES (continued)

Recent Accounting Pronouncements

In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity ("ASU 2020-06"), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. This ASU (1) simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock; (2) revises the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer's own stock and classified in stockholders' equity, by removing certain criteria required for equity classification; and (3) revises the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. For SEC filers, excluding smaller reporting companies, ASU 2020-06 is effective for fiscal years beginning after December 15, 2021 including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. For all other entities, ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Entities should adopt the guidance as of the beginning of the fiscal year of adoption and cannot adopt the guidance in an interim reporting period. The Company is currently evaluating the impact that ASU 2020-06 may have on its financial statements and related disclosures.

In March 2023, the FASB issued ASU 2023-01, Lease (Topic 842): Common Control Arrangements, which clarifies the accounting for leasehold improvements associated with leases between entities under common control (hereinafter referred to as common control lease). ASU 2023-01 requires entities to amortize leasehold improvements associated with common control lease over the useful life to the common control group (regardless of the lease term) as long as the lessee controls the use of the underlying asset through a lease, and to account for any remaining leasehold improvements as a transfer between entities under common control through an adjustment to equity when the lessee no longer controls the underlying asset. This ASU will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been made available for issuance. An entity may apply ASU 2023-01 either prospectively or retrospectively. The Company is currently evaluating the impact that the adoption of ASU 2023-01 will have on its consolidated financial statement presentation and disclosures.

CBD OF DENVER, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

Note 2 - Debt

Notes payable - CBDD

Notes payable amounted to \$253,214 as of December 31, 2021. On February 7, 2020, the Company entered into an agreement with the note holder in which principal, interest and penalties totaling \$813,214.11 (the "Debt") would be exchanged for 1,000,000,000 (one billion) shares of the Company's common stock. In conjunction with this settlement, the Company recorded interest expense in the quarter ended March 31, 2020 of \$178,390. The Company's common stock closed at \$0.0007 per share on February 7, 2020, and consequently the value of the shares of common stock to be issued to satisfy the Debt is \$700,000.

The note holder make take down from time-to-time, upon the request of the holder (each a "Takedown Request"), any number of shares it desires, so long as the number of shares of common stock issuable upon a Takedown Request does not result in beneficial ownership by the holder, together with its affiliates and any persons acting as a group together with the holder, of more than 9.99% of the outstanding shares of common stock of the Company

As of December 31, 2020, the Company has issued 800,000,000 shares of common stock to the note holder. The issuance was recorded as a reduction in accrued interest and penalties, which are recorded as a component of accrued expenses on the Company's balance sheet, and as a reduction in notes payable. The total reduction in liabilities as of December 31, 2020, due to the issuance of stock in conjunction with the debt settlement agreement, amounts to \$560,000, leaving an outstanding balance of \$253,214.11. Upon issuance of an additional 200,000,000 shares of common stock the Debt will be satisfied, and any existing notes shall be cancelled.

On March 16, 2022, the Company issued 200,000,000 shares of common stock to settle the balance of the Debt. The Company's common stock closed at \$0.0038 per share on March 16, 2022, and consequently the value of the shares of common stock issued amounted to \$760,000, resulting a loss on debt settlement of \$506,786.

Capitoline Ventures LLC Note

On March 8, 2023, the Company issued a convertible grid promissory note to Capitoline Ventures LLC with a maturity date of September 8, 2023. During the term, the Company may borrow, from time to time hereunder up to an aggregate amount not exceed the sum of \$730,234.92. the lender has advanced the principal amount to the Company from 2020 through 2022. The principal balance of the note outstanding form time to time shall bear interest at a rate of 12% per annum. The holder of this note is entitled to convert all or any lesser portion of the outstanding principal amount and accrued but unpaid interest into common stocks pursuant to the terms outlined in the note agreement. As of March 31, 2025, the outstanding balance of the note, including accrued interest, amounted to \$897,896. As of December 31, 2024, the outstanding balance of the note, including accrued interest, amounted to \$875,966.

CBD OF DENVER, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

Note 2 - Debt (continued)

Pascal Siegenthaler Note

On March 8, 2023, the Company issued a convertible grid promissory note to Pascal Siegenthaler with a maturity date of September 8, 2023. During the term, the Company may borrow, from time to time hereunder up to an aggregate amount not exceed the sum of \$69,000. the lender has advanced the principal amount to the Company from 2020 through 2022. The principal balance of the note outstanding from time to time shall bear interest at a rate of 12% per annum. The holder of this note is entitled to convert all or any lesser portion of the outstanding principal amount and accrued but unpaid interest into common stocks pursuant to the terms outlined in the note agreement. As of December 31, 2023, the outstanding balance of the note, including accrued interest, amounted to \$81,484, which exceeded the maximum amount of \$69,000. As of December 31, 2024, the outstanding balance of the note, including accrued interest, amounted to \$89,764, which exceeded the maximum amount of \$69,000. On February 3, 2025, the note and the accrued interest was converted into 310,143,730 common shares.

Note 3 - CAPITAL STOCK

Authorized Capital

The Company was authorized to issue 7,000,000,000 shares of its common stock, par value \$0.00001 and 100,000,000 shares of preferred stock, par value \$0.00001. On July 21, 2022, the Company filed a certificate of designation with the State of Delaware to designate 1,500,000 shares of the authorized and unissued preferred stock as "Series B Preferred Stock". On January 12, 2023, 10,000,000 shares of the authorized and unissued preferred stock as "Series C Preferred Stock". 1 shares of the authorized and unissued preferred stock as "Series C Preferred Stock". Accordingly, 88,500,000 shares remained as authorized "Series A Preferred Stock".

Stock Issuance

Outstanding shares Series B Preferred Stock shall accrue a dividend at the rate of 5% per annum of the Series B Original Issued Price, which shall mean \$10 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series B Preferred Stock. Such accrued and unpaid dividend shall be convertible to shares of common stock on the basis set forth below. Dividends shall not accrue on any shares that have been converted.

Each share of Series B Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into that number of fully paid and nonassessable shares of common stock (whether whole or fractional) that have a "Fair Market Value", in the aggregate, equal to Series B Original Issued Price, as adjusted as provided herein. "Fair Market Value" shall mean as of any date of determination, 80% of the average closing price of a share of common stock on the principal exchange or market on which such shares are then trading for the 5 trading days immediately preceding such date. Therefore, to determine the number of shares issuable, the Series B Original Issue Price, as adjusted, is divided by the Fair Market Value, the quotient being the number of shares of common stock issued upon conversion.

CBD OF DENVER, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

Note 3 - CAPITAL STOCK (continued)

Outstanding shares Series C Preferred Stock shall accrue a dividend at the rate of 5% per annum of the Series C Original Issued Price, which shall mean \$1 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series C Preferred Stock. Such accrued and unpaid dividend shall be convertible to shares of common stock on the basis set forth below. Dividends shall not accrue on any shares that have been converted.

On July 21, 2022, 5,000 shares of Series B Preferred Stock were issued to an investor for \$50,000.

On September 22, 2022 2,000 shares of Series B Preferred Stock were issued to an investor for \$20,000.

On December 7, 2022 5,000 shares of Series B Preferred Stock were issued to an investor for \$50,000.

In July 2022, 2,666,666 shares of common stock were issued to an investor at \$0.0075 per share, totaling \$20,000, and 2,000,000 shares of common stock were issued to the same investor at \$0.015 per share, totaling \$30,000.

In August 2022, 67,200,000 shares of common stock were issued to five investors at a price per share equal to 75% of the average VWAP for the five trading days prior to issuance, totaling \$140,500. The Investors will receive a Warrant to purchase that number of shares of Company Common Stock equal to the number of shares of Common Stock purchased. The Warrant shall have an exercise price equal to 200% of the Common Share Purchase Price, The Warrants shall be exercisable for a period of three years from the effective date of the reverse split of the Company's common stock.

As of December 31, 2022, 10,000,000 shares of Series A Preferred Stock, 12,000 shares of Series B Preferred Stock, and 5,581,454,773 shares of common stock were issued and outstanding.

On January 25, 2023, 68,933,333 shares of common stocks were issued for \$103,400, which was used to pay off portion of the accounts payable.

In March 2023, 9,966,000 shares of Preferred A Stocks were converted into 9,966,000 shares of Preferred C Stocks, of which, 233,074 shares of Preferred C Stocks were subsequently converted into 349,611,000 shares of common stocks.

On August 1, 2023, 166,667 shares of Preferred C Stocks were converted into 250,000,500 shares of common stocks.

On August 1, 2023, 102,000,000 shares of common stocks were issued to three directors, valued at \$0.0004 per share, the closing price of the Company's common stocks trading on OTC Market.

CBD OF DENVER, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

Note 3 - CAPITAL STOCK (continued)

On August 1, 2023, 30,180,000 shares of common stocks were issued to two investors for \$12,072, at \$0.0004 per share. The proceeds was used to pay off the company's expenses in the third quarter 2023.

As of September 30, 2023, 34,000 shares of Series A Preferred Stock, 12,000 shares of Series B Preferred Stock, 9,566,259 shares of Series C Preferred Stock, and 6,382,179,606 shares of common stock were issued and outstanding.

As of March 31, 2025, 34,000 shares of Series A Preferred Stock, 12,000 shares of Series B Preferred Stock, 9,566,259 shares of Series C Preferred Stock, and 8,925,546,030 shares of common stock were issued and outstanding

Note 4 - COMMITMENTS AND CONTINGENCIES

Litigation

The Company accrues for loss contingencies associated with outstanding litigation, claims and assessments for which management has determined it is probable that a loss contingency exists, and the amount of loss can be reasonably estimated. Costs for professional services associated with litigation claims are expensed as incurred. As of March 31, 2025 and December 31, 2024, the Company had not accrued or incurred any amounts for litigation matters.

Leases

CBD of Denver has no long-term leases.

Note 5 - SUBSEQUENT EVENTS

The Company evaluated subsequent events through the date of issuance of these financial statements. We are not aware of any significant events that occurred subsequent to the balance sheet date but prior to the issuance of this report that would have a material impact on our financial statements.